
Shares of drug developer Enliven Therapeutics ELVN.O down 1.7% at $19.82
Enliven appoints Rick Fair as chief executive officer, effective December 11
Sam Kintz, co-founder and former CEO of Enliven, will assume a new role as Head of Pipeline, effective December 11
Enliven plans to initiate a late-stage study of its experimental drug, ELVN-001, in patients with chronic myeloid leukemia in 2026
Including session's moves, stock down 10.4% YTD